Search research articles
Contact Us
Filters
Showing results (51-60 of 90) with videos related to
Page
of 9
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
March 3, 2023
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)
Alain Vergnenegre, Isabelle Monnet, Charles Ricordel, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
December 19, 2017
Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma
Nicolas Piton, Philippe Ruminy, Claire Gravet, et al.
International Journal of Molecular Sciences
|
November 20, 2019
Upgrading the Repertoire of miRNAs in Gastric Adenocarcinoma to Provide a New Resource for Biomarker Discovery
Michelle E Pewarchuk, Mateus C Barros-Filho, Brenda C Minatel, et al.
Journal of Geriatric Oncology
|
May 21, 2023
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study
Sébastien Gendarme, Sonia Zebachi, Romain Corre, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 7, 2019
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)
Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, et al.
The Lancet. Respiratory Medicine
|
November 1, 2024
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study
Hervé Léna, Laurent Greillier, Claire Cropet, et al.
Journal of Cancer Research and Clinical Oncology
|
August 25, 2023
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
Hélène Doubre, Laurent Greillier, Grégoire Justeau, et al.
Journal for Immunotherapy of Cancer
|
September 7, 2023
Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer
Pierre Decazes, Samy Ammari, Younes Belkouchi, et al.
JTO Clinical and Research Reports
|
January 24, 2025
Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC
Francesca Lucibello, Valérie Gounant, Mihaela Aldea, et al.
Cancers
|
April 12, 2022
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
Renaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 90) with videos related to
Sort By:
Page
of 9
Lung Cancer (Amsterdam, Netherlands)
|
March 3, 2023
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)
Alain Vergnenegre, Isabelle Monnet, Charles Ricordel, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
December 19, 2017
Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma
Nicolas Piton, Philippe Ruminy, Claire Gravet, et al.
International Journal of Molecular Sciences
|
November 20, 2019
Upgrading the Repertoire of miRNAs in Gastric Adenocarcinoma to Provide a New Resource for Biomarker Discovery
Michelle E Pewarchuk, Mateus C Barros-Filho, Brenda C Minatel, et al.
Journal of Geriatric Oncology
|
May 21, 2023
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study
Sébastien Gendarme, Sonia Zebachi, Romain Corre, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 7, 2019
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)
Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, et al.
The Lancet. Respiratory Medicine
|
November 1, 2024
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study
Hervé Léna, Laurent Greillier, Claire Cropet, et al.
Journal of Cancer Research and Clinical Oncology
|
August 25, 2023
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
Hélène Doubre, Laurent Greillier, Grégoire Justeau, et al.
Journal for Immunotherapy of Cancer
|
September 7, 2023
Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer
Pierre Decazes, Samy Ammari, Younes Belkouchi, et al.
JTO Clinical and Research Reports
|
January 24, 2025
Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC
Francesca Lucibello, Valérie Gounant, Mihaela Aldea, et al.
Cancers
|
April 12, 2022
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
Renaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, et al.
Page
of 9